The GCI Dashboard

Version:
Share: whatsapp
Country Rank

151


Australia

Recovery Rank for 180 countries/regions

Country Rank

67


Australia

Recovery Rank for 184 countries/regions

COVID-19 Recovery Rating

2

Recovery Index
44.62
(Out of 100)



(100 = Best, 0 = Worst)

COVID-19 Recovery Rating

3

Recovery Index
55.25
(Out of 100)



(100 = Best, 0 = Worst)

COVID-19 Severity Rating

5

Severity Index
71.58
(Out of 100)



(0 = Best, 100 = Worst)

COVID-19 Severity Rating

2

Severity Index
41.01
(Out of 100)



(0 = Best, 100 = Worst)

Stringency Rating

N/A

(100 = Strictest Measures, 0 = No Measures)


Population
25,364,307

(Low Density)


GNI per capita (US$)

53,250

(High income)
5 Countries who have made the most progress in
curtailing the spread of the pandemic and can be
used as examples of best practices (Relative Rating)

4
3
2 Countries who are struggling to cope with the crisis
and who may need to consider maintaining stringent
non-pharmaceutical measures (Relative Rating)
1
1 Countries who are coping with the crisis with a low percentage
of infections and resulting deaths per population
(Relative Rating)
2
3 Countries who may be overwhelmed by the crisis with a high
percentage of infections and resulting deaths per population
(Relative Rating)
4
5

Travel Advisory


1. Passengers are not allowed to enter. - This does not apply to: - nationals of Australia and their immediate family members; - permanent residents of Australia and their
immediate family members; - nationals of New Zealand residing in Australia and their immediate family members; - passengers who have only been in Australia or New Zealand in the
past 14 days; - nationals of Japan, Korea (Rep.) and Singapore arriving directly from their country of nationality with a COVID-19 vaccination certificate showing that they were
fully vaccinated at least 7 days before departure. Vaccines accepted are AstraZeneca (Vaxzevria), AstraZeneca (Covishield), Covaxin, Janssen, Moderna (Spikevax), Pfizer-BioNTec
(Comirnaty), Sinopharm (BIBP) (for passengers younger than 60 years only) and Sinovac; - nationals of Japan, Korea (Rep.) and Singapore younger than 18 years and older than 11
years arriving directly from their country of nationality and traveling with their vaccinated parents/guardians; - nationals of Japan, Korea (Rep.) and Singapore younger than 12
years arriving directly from their country of nationality; - passengers with a COVID-19 vaccination certificate showing that they were fully vaccinated at least 7 days before
departure and a visa issued by Australia listed at https://covid19.homeaffairs.gov.au/vaccinated-travellers . Vaccines accepted are AstraZeneca (Vaxzevria), AstraZeneca
(Covishield), Covaxin, Janssen, Moderna (Spikevax), Pfizer-BioNTec (Comirnaty), Sinopharm (BIBP) (for passengers younger than 60 years only) and Sinovac; - passengers with a
Special Purpose Visa; - military personnel participating in military activities sponsored by Australian Department of Defence.

2. Passengers entering or transiting through Australia must have a negative COVID-19 PCR test taken at most 3 days before departure from the first embarkation point. More details
can be found at https://tinyurl.com/y398dxv4 - This does not apply to: - passengers younger than 5 years; - passengers arriving from Kiribati, Myanmar, Niue, Samoa, Solomon Isl.,
Tokelau, Tonga, Tuvalu or Vanuatu; - passengers arriving from Belize, Cook Isl., Fiji, French Polynesia, Marshall Isl., Micronesia (Federated States), Nauru, New Caledonia, Palau,
Papua New Guinea, Timor-Leste or Wallis and Futuna Isl.

3. Passengers entering or transiting through Australia from Belize, Cook Isl., Fiji, French Polynesia, Marshall Isl., Micronesia (Federated States), Nauru, New Caledonia, Palau,
Papua New Guinea, Timor-Leste or Wallis and Futuna Isl. must have a negative COVID-19 PCR test taken at most 96 hours before departure from the first embarkation point. More
details can be found at https://tinyurl.com/y398dxv4 - This does not apply to passengers younger than 5 years.

4. Passengers traveling above the passenger caps, must have a COVID-19 vaccination certificate showing that they were fully vaccinated at least 7 days before departure. Vaccines
accepted are AstraZeneca (Vaxzevria), AstraZeneca (Covishield), Covaxin, Janssen, Moderna (Spikevax), Pfizer-BioNTec (Comirnaty), Sinopharm (BIBP) (for passengers younger than 60
years only) and Sinovac. - This does not apply to: - passengers younger than 12 years traveling with a fully vaccinated parent/guardian; - nationals of Australia between 12 and 17
years traveling with a fully vaccinated parent/guardian and arriving in Australian Capital Territory, New South Wales or Victoria.

5. Passengers are not allowed to transit through Australia to New Zealand for more than 72 hours. - This does not apply to passengers with an exemption applied at
https://immi.homeaffairs.gov.au/help-support/departmental-forms/online-forms/covid19-enquiry-form

6. Passengers must have a "Travel Declaration" form and present it at time of check-in. The form can be found at https://covid19.homeaffairs.gov.au/australia-travel-declaration

7. Passengers could be subject to quarantine for 14 days at the first point of entry. Details can be found at https://www.australia.gov.au/states

8. Airline crew are subject to quarantine until their next flight. Quarantine arrangements for airline crew are subject to respective state or territory requirements.

9. Passengers transiting through Australia for 8 to 72 hours to a third country are subject to quarantine until their next flight. - This does not apply to passengers with a
COVID-19 vaccination certificate showing that they were fully vaccinated.

Travel Advisory information provided and published with permission by IATA. (Timatic COVID-19 Alerts Service has been discontinued on 1/1/2022, please refer this page for latest travel advisory)


Australia Infection Trend


How can you tell if a curve is really flattening?

The number of daily confirmed cases has been used as an estimation of how severe the COVID-19 situation is in a given country. However, we’ve found that focusing on the country’s cumulative number of active cases gives a clearer picture of whether the infection curve is flattening.


Countries with Similar Characteristics


This table is generated by a GCI-developed tool to match countries based on their similar characteristics such as population, population density, income and climate.

Australia 55.25 44.62 25,364,307 Low Density High income 26-30 deg
Country Recovery Index Recovery Index Population Density GNI per capita Average Temperature
since First Case (Celsius)
Match%
Saudi Arabia 76.27 81.03 34,268,528 Low Density High income 26-30 deg 100%
Canada 75.10 66.34 37,589,262 Low Density High income < 10 deg 85%
Chile 72.37 75.18 18,952,038 Low Density High income < 10 deg 85%
Somalia 40.93 52.30 15,442,905 Low Density Low income 26-30 deg 75%
South Sudan 51.50 54.29 11,062,113 Low Density Low income 26-30 deg 75%
Algeria 23.00 45.62 43,053,054 Low Density Lower middle income 21-25 deg 60%
Angola 50.24 56.66 31,825,295 Low Density Lower middle income 21-25 deg 60%
Argentina 53.38 58.75 44,938,712 Low Density Upper middle income 11-20 deg 60%
Bolivia 36.64 41.32 11,513,100 Low Density Lower middle income 21-25 deg 60%
Chad 47.46 56.60 15,946,876 Low Density Low income > 30 deg 60%

GCI Recovery Forecast


The GCI Recovery Forecasting methodology relies on a Monte Carlo simulation model as we recognise that the factors that contribute to an increase / decrease in confirmed COVID19 cases are highly variable and subject to various localised circumstances and interventions. The P10 / P50 / P90 are probabilities assigned to the forecasts, with P10 being highly optimistic, and P90 being very conservative on recovery and reduction in cases. The forecast model is updated daily based on the latest case data.

Forecast Results:

Situation May Improve. The GCI Model indicates that the situation has a small probability of recovery, but there is insufficient evidence to suggest that the recovery trend will improve significantly in the near future.




Reviewed and Endorsed by:

In Collaboration and
Partnership with:

image

Recognition and Award:

Chairman's Award



Key Sponsor: